Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04878497
Other study ID # 2019P000110-NOAC
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date March 30, 2021
Est. completion date December 31, 2022

Study information

Verified date May 2021
Source Brigham and Women's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this study is to establish a near-real-time prospective monitoring program in Medicare, Optum and MarketScan Research data to evaluate the benefit of new cardiovascular disease (CVD) drugs for older adults with frailty. Prospective monitoring program seeks to find early effectiveness and safety signals of new drugs by updating the analysis at regular intervals as new Medicare data become available. This study specifically aims to emulate a prospective surveillance of the effectiveness and safety of non-vitamin K oral anticoagulants (NOAC) vs. a comparator, warfarin, in older adults with atrial fibrillation and different frailty status. This program will be enhanced by incorporating a novel claims-based frailty index, which has been shown useful in assessing how the benefits and harms of drug therapy vary by frailty.


Description:

Data sources of use for this study are: Medicare Database, Optum Database, and MarketScan Research Database. All data from years 2013-2020 (available data may vary depending on the database) will be analyzed in the study. This study follows a sequential cohort monitoring design. The monitoring analysis will include 1) retrospective analysis of available data (2013-2018) at the time of first analysis (April 2021) and 2) prospective analysis of new data (2019-2020) as they become available to the researchers. Within each database and by frailty status (frail vs non-frail), the investigators will emulate annual updating of data by creating a propensity score (PS)-matched cohort of new users every 1-year interval. Each sequential cohort will be followed for development of the outcomes of interest. At the end of each interval, time-to-event data from all sequential cohorts will be pooled for outcome analysis. The surveillance will be performed by frailty status (frail vs non-frail) at the time of drug initiation.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1000000
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Initiation of a NOAC or warfarin (day 0 is the initiation day) - Continuous enrollment in medical and drug insurance in [-183, 0] days - Diagnosis of AF in [-183, 0] days - CHA2DS2-VASc score =2 (moderate or high risk for stroke) - No prior use of NOAC or warfarin in [-183, -1] days - No recent hospitalization for stroke or major bleeding in [-60, 0] days - No recent nursing facility stay in [-60, 0] days Exclusion Criteria: - Contraindication to either drug in [-183, 0] days - Valvular heart disease or mechanical heart valve in [-183, 0] days - Intracranial or retroperitoneal hemorrhage in [-183, 0] days - Chronic kidney disease stage V, end-stage renal disease, or dialysis in [-183, 0] days - Other indications for anticoagulation therapy in [-183, 0] days

Study Design


Intervention

Drug:
Warfarin
Initiation of warfarin, identified using prescription fill in pharmacy claims
Dabigatran
Initiation of dabigatran, identified using prescription fill in pharmacy claims
Rivaroxaban
Initiation of rivaroxaban, identified using prescription fill in pharmacy claims
Apixaban
Initiation of apixaban, identified using prescription fill in pharmacy claims
Edoxaban
Initiation of edoxaban, identified using prescription fill in pharmacy claims

Locations

Country Name City State
United States Brigham and Women's Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with composite events of stroke or systemic embolism Stroke OR systemic embolism, identified by relevant diagnoses in the claims data January 2013 - December 2020 (after drug initiation)
Primary Number of patients with major bleeding Major bleeding, identified by relevant diagnoses in the claims data January 2013 - December 2020 (after drug initiation)
Secondary Number of patients with all-cause mortality All-cause mortality is defined by the National Death Index file or vital status information in the claims data. January 2013 - December 2020 (after drug initiation)
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Recruiting NCT05993221 - Deconstructing Post Stroke Hemiparesis